7 Retatrutide Phase 3 Trials Coming in 2026: Complete Timeline
🚀 2026 is Retatrutide's Pivotal Year
With today's TRANSCEND-T2D-1 success (March 19, 2026), Eli Lilly confirmed 7 additional Phase 3 trials will report results before year-end. This means 8 total Phase 3 readouts in 2026 — enough for FDA submission and approval by late 2026/early 2027.
📊 Complete 2026 Trial Timeline
| # | Trial | Indication | Results | Status |
| 1 | TRANSCEND-T2D-1 | Type 2 Diabetes | ✅ March 19, 2026 | SUCCESS |
| 2 | TRANSCEND-T2D-2 | Diabetes + Background Therapy | Q2 2026 | Ongoing |
| 3 | TRANSCEND-T2D-3 | Diabetes + CV Risk | Q2-Q3 2026 | Ongoing |
| 4 | TRIUMPH-1 | Obesity (Flagship) | Q3 2026 | Ongoing |
| 5 | TRIUMPH-2 | Obesity + Comorbidities | Q3-Q4 2026 | Ongoing |
| 6 | TRIUMPH-3 | Weight Maintenance | Q4 2026 | Ongoing |
| 7 | TRIUMPH-5 | 4mg Maintenance Dose | Q4 2026 | Ongoing |
| 8 | TRIUMPH-6 | MASH/Liver Disease | Q4 2026 | Ongoing |
📅 Key Upcoming Trials
TRIUMPH-1 (Q3 2026) - Most Important
The flagship obesity trial similar to SURMOUNT-1 (tirzepatide) and STEP-1 (semaglutide). Expected results based on Phase 2:
- 24-28% weight loss at 72 weeks (highest dose)
- vs. Zepbound: 21% at 72 weeks
- vs. Wegovy: 15% at 68 weeks
TRANSCEND-T2D-3 (Q2-Q3 2026) - CV Safety
The cardiovascular outcomes trial testing safety in high-risk diabetes patients. Critical for:
- FDA approval requirements
- Insurance coverage breadth
- Possible CV indication label
TRIUMPH-6 (Q4 2026) - MASH Treatment
Liver disease trial showing potential for MASH treatment. Phase 2 results showed 80% liver fat reduction — potentially game-changing for fatty liver disease.
🎯 FDA Approval Timeline
Late 2026: FDA Submission
After all 8 trials complete, Lilly will compile and submit the New Drug Application (NDA) for diabetes and obesity indications.
Q1 2027: FDA Approval (Expected)
- Best case: Late 2026 (priority review)
- Likely case: Q1 2027 (standard review)
- Worst case: Q2 2027 (if FDA requests more data)
2027-2028: Market Launch
- Initial launch: Limited supply (like Zepbound/Wegovy)
- Full availability: 12-18 months post-approval
❓ FAQs
How many trials does retatrutide need for approval?
Typically 2 successful Phase 3 trials per indication. Lilly is running 8 trials to maximize label claims:
- Diabetes: 3 trials (TRANSCEND program)
- Obesity: 4 trials (TRIUMPH program)
- MASH: 1 trial (TRIUMPH-6)
When can I get retatrutide?
Late 2026 to Q1 2027 if FDA approval goes as expected. Full availability by late 2027.
What if a trial fails?
Very unlikely given today's success and strong Phase 2 data. Even if 1-2 trials miss endpoints, Lilly can still file with remaining successful trials.
✅ Bottom Line
8 Phase 3 trials in 2026 = pivotal year for retatrutide:
- ✅ March 19: First diabetes trial success
- ✅ Q2-Q4 2026: 7 more trials complete
- ✅ Late 2026: FDA submission
- ✅ Q1 2027: Potential approval
Can't wait? Start with tirzepatide (Mounjaro/Zepbound) now and switch when retatrutide launches.
Last updated: March 19, 2026
Can't wait for retatrutide? Talk with a clinician about GLP-1 care available today.
Retatrutide is not for sale. These telehealth partners offer clinician consults for other GLP-1 options available today. They do not sell retatrutide.
Compounded GLP-1 + GIP via telehealth. Not Zepbound, not Mounjaro, not retatrutide. Compounded medication is not FDA-approved. Medical consultation required.
Semaglutide & tirzepatide with licensed physicians. Includes medical consultation.
Compounded semaglutide & tirzepatide. Fast shipping, no hidden fees.
NextGenGLP1 may earn a commission at no cost to you. Compounded medication is not FDA-approved. A prescription is issued only after a medical consultation. Pricing on partner sites can change.